Canbridge broadens investor syndicate with $43M series E

The addition of $43 million in new series E cash to Canbridge’s balance sheet may better prepare it for a listing, but the company isn’t saying when or where it might go public.

At the time of its $98 million series D round in February, China-based in-licensing play Canbridge Pharmaceuticals Inc. had signaled its appetite for a public offering. CBO and CFO Glenn Hassan told BioCentury at the time that the company was considering a listing within 12-24 months, with U.S. and Chinese exchanges under consideration...